Analystreport

OptimizeRx Corp. (NYSE: OPRX) had its "buy" rating re-affirmed by analysts at B. Riley.

OptimizeRx Corporation  (OPRX) 
NASDAQ:AMEX Investor Relations: optimizerx.com/investors